SGMO stock is one of the notable biotech stock gainers in Monday’s trading session after Sangamo Therapeutics Inc (NASDAQ:SGMO) issued solid results for a new drug to treat severe hemophilia A.
Encouraging ResultsCalifornia-based biotechnology company Sangamo Therapeutics Inc was on a tear back in April this year after results were released from two patients who had been treated with its hemophilia medicine SB 525.
Today, the company released data from its Phase 1/2 ALTA study of SB 525 with regards to the effects on patients who suffer from hemophilia. It is a hugely ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.